Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Halozyme Therapeutics Inc Stock Research

HALO

37.69USD-0.51(-1.34%)Market Closed
Watchlist

Market Summary

USD37.69-0.51
Market Closed
-1.34%

HALO Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

HALO Stock Price

HALO RSI Chart

HALO Valuation

Market Cap

5.0B

Price/Earnings (Trailing)

21.26

Price/Sales (Trailing)

6.42

EV/EBITDA

14.79

Price/Free Cashflow

16.97

HALO Price/Sales (Trailing)

HALO Profitability

EBT Margin

32.16%

Return on Equity

275.83%

Return on Assets

10.69%

Free Cashflow Yield

5.89%

HALO Fundamentals

HALO Revenue

Revenue (TTM)

773.7M

Revenue Y/Y

45.07%

Revenue Q/Q

36.32%

HALO Earnings

Earnings (TTM)

233.7M

Earnings Y/Y

229.53%

Earnings Q/Q

88.7%

Price Action

52 Week Range

29.8559.46
(Low)(High)

Last 7 days

-3.1%

Last 30 days

-12.0%

Last 90 days

2.2%

Trailing 12 Months

-4.7%

HALO Financial Health

Current Ratio

6.69

Debt/Equity

22.67

Debt/Cashflow

0.19

HALO Investor Care

Buy Backs (1Y)

4.41%

Diluted EPS (TTM)

1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for HALO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-19
LaBarre Michael J.
acquired
199,800
19.98
10,000
svp, chief technical officer
2023-09-19
LaBarre Michael J.
sold
-390,980
39.098
-10,000
svp, chief technical officer
2023-08-31
Torley Helen
sold
-428,170
42.817
-10,000
president and ceo
2023-08-31
Torley Helen
acquired
138,700
13.87
10,000
president and ceo
2023-08-30
Torley Helen
acquired
138,700
13.87
10,000
president and ceo
2023-08-30
Torley Helen
sold
-428,540
42.854
-10,000
president and ceo
2023-08-29
Torley Helen
sold
-424,020
42.402
-10,000
president and ceo
2023-08-29
Torley Helen
acquired
138,700
13.87
10,000
president and ceo
2023-08-22
LaBarre Michael J.
acquired
196,778
19.6778
10,000
svp, chief technical officer
2023-08-22
LaBarre Michael J.
sold
-424,070
42.407
-10,000
svp, chief technical officer

1–10 of 50

Which funds bought or sold HALO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
44.29
2,695,000
10,129,000
0.01%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
-32,860
559,085
0.48%
2023-09-12
Farther Finance Advisors, LLC
added
500
891
1,082
-%
2023-08-29
EFG Asset Management (Americas) Corp.
added
20.00
34,005
288,885
0.07%
2023-08-24
Alberta Investment Management Corp
new
-
558,003
558,003
-%
2023-08-23
Rehmann Capital Advisory Group
unchanged
-
-745
36,545
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-95.00
-7,641,160
378,735
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
32.2
121,837
594,734
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-6.95
-813,053
5,900,370
0.01%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
10.27
35,000
879,000
0.01%

1–10 of 40

Latest Funds Activity

Are funds buying HALO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HALO
No. of Funds

Schedule 13G FIlings of Halozyme Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 09, 2023
vanguard group inc
10.27%
13,528,630
SC 13G/A
Feb 10, 2023
invesco ltd.
5.2%
7,036,951
SC 13G
Feb 10, 2023
blackrock inc.
14.2%
19,196,061
SC 13G/A
Feb 10, 2023
artisan partners limited partnership
5.3%
7,140,953
SC 13G/A
Feb 09, 2023
vanguard group inc
9.84%
13,303,847
SC 13G/A
Jan 26, 2023
blackrock inc.
13.6%
18,214,071
SC 13G/A
Jan 20, 2023
blackrock inc.
13.6%
18,214,071
SC 13G
Feb 04, 2022
artisan partners limited partnership
6.8%
9,505,768
SC 13G/A
Jan 28, 2022
blackrock inc.
13.8%
19,439,863
SC 13G/A
Feb 12, 2021
bb biotech ag
2.9%
3,970,000
SC 13G/A

Recent SEC filings of Halozyme Therapeutics

View All Filings
Date Filed Form Type Document
Sep 19, 2023
144
Notice of Insider Sale Intent
Sep 19, 2023
4
Insider Trading
Sep 07, 2023
8-K
Current Report
Aug 31, 2023
144
Notice of Insider Sale Intent
Aug 31, 2023
4
Insider Trading
Aug 30, 2023
144
Notice of Insider Sale Intent
Aug 29, 2023
144
Notice of Insider Sale Intent
Aug 23, 2023
4
Insider Trading
Aug 22, 2023
144
Notice of Insider Sale Intent
Aug 17, 2023
4
Insider Trading

Peers (Alternatives to Halozyme Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
142.4B
26.6B
3.74% 20.01%
17.85
5.36
0.75% 21.34%
92.4B
27.4B
-3.33% 22.27%
16.85
3.37
-0.48% 32.56%
39.4B
10.7B
-8.22% -12.63%
32.61
3.69
-53.67% -91.41%
36.6B
10.0B
-5.36% -5.30%
13.73
3.67
-6.23% 29.40%
MID-CAP
10.9B
1.7B
1.05% 5.25%
61.85
6.52
29.01% 1345.90%
4.1B
-
-16.91% 155.63%
-7.02
48.33
54.84% -12.96%
2.7B
-
-15.10% -35.52%
-21.18
37.44
122.90% 54.78%
1.7B
80.2M
-8.35% -54.87%
-5.12
20.91
42.17% -39.82%
SMALL-CAP
1.3B
121.2M
-18.44% -33.91%
-4.48
10.62
-70.36% -531.73%
931.2M
15.3M
-19.93% -8.57%
-5.13
60.82
1090.59% -36.57%
668.6M
1.6B
-13.64% -61.04%
-1.14
0.42
23.74% 60.24%
189.2M
-
-31.67% -91.43%
-0.89
1.38
116.83% 16.61%
113.0M
2.1M
-10.53% -65.89%
-1.12
55
487.70% -8.66%
104.6M
-
-38.94% -87.76%
-0.53
0.43
113.96% -15.19%
6.3M
-
5.48% -92.77%
-0.08
3.21
- -129.46%

Halozyme Therapeutics News

Best Stocks
New Mexico Educational Retirement Board Increases Stake in ....
Best Stocks,
10 hours ago

Returns for HALO

Cumulative Returns on HALO

13.2%


10-Year Cumulative Returns

17.4%


7-Year Cumulative Returns

15.1%


5-Year Cumulative Returns

13.5%


3-Year Cumulative Returns

Risks for HALO

What is the probability of a big loss on HALO?

85.4%


Probability that Halozyme Therapeutics stock will be more than 20% underwater in next one year

28.5%


Probability that Halozyme Therapeutics stock will be more than 30% underwater in next one year.

11.2%


Probability that Halozyme Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HALO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Halozyme Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Halozyme Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue9.7%774705660581487472443463412331268200180164196203182178152281319
Costs and Expenses1.8%468459393331246171167166151133123165211238264238218221221225229
  S&GA Expenses-11.1%14916714412098.0053.0050.0047.0046.0044.0046.0059.0066.0072.0077.0071.0068.0065.0061.0058.0056.00
  R&D Expenses5.8%77.0073.0067.0054.0046.0039.0036.0033.0032.0033.0034.0072.0095.00120141132137144150155153
EBITDA-100.0%-25527225224530525928124618415344.00-19.82-62.49-56.56------
EBITDA Margin-100.0%-0.36*0.41*0.43*0.50*0.65*0.58*0.61*0.60*0.55*0.57*0.22*-0.11*-0.38*-0.29*------
Interest Expenses7.0%21.0020.0017.0014.009.007.008.0011.0014.0017.0020.0019.0016.0014.0012.0012.0014.0016.0018.0020.0021.00
Earnings Before Taxes27.8%29022724923323329524926722916312922.00-39.68-80.16-72.25-39.60-42.45-50.70-79.7944.0075.00
EBT Margin-100.0%-0.32*0.38*0.40*0.48*0.63*0.56*0.58*0.56*0.49*0.48*0.11*-0.22*-0.49*-0.37*------
Net Income28.7%23418220221136643540340922916312922.00-39.70-80.14-72.24-39.97-42.80-51.07-80.3346.0076.00
Net Income Margin-100.0%-0.26*0.31*0.36*0.75*0.92*0.91*0.88*0.55*0.49*0.48*0.11*-0.22*-0.49*-0.37*------
Free Cashflow-100.0%-26423523829028729826515011653.00-23.54-60.14-89.07-89.46------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets6.5%1,8101,6991,8421,8651,7811,1621,1041,1851,026967580524527492566370418429440445475
  Current Assets24.5%7666157396535429899261,0171,000942555499500468543342392409428430462
    Cash Equivalents129.5%22196.0023414791.0011811949244750014866.0013410512160.0068.0061.0058.0056.0056.00
  Inventory23.1%13210810010398.0048.0054.0056.0059.0058.0061.0058.0048.0041.0029.0036.0044.0031.0023.0018.008.00
  Net PPE---------10.0010.0011.0010.0011.0012.0011.0015.0015.0015.007.007.005.00
  Goodwill0.1%417416409199199----------------
Liabilities1.6%1,6591,6341,672------------------
  Current Liabilities26.6%11692.0013110920011211711311410742127.0026.0042.0086.00108135139149139132
  Long Term Debt---1,493-1,147788787786786785-3943903873839.0014.0019.0035.0058.0079.00
    LT Debt, Current---13.0013.0099.0090.0089.0089.0089.0089.00397--3.0020.0055.0071.0087.0092.0089.0087.00
    LT Debt, Non Current0.1%1,4961,4941,4931,491--787--------------
Shareholder's Equity129.4%15166.0017097.0029326019728212068.0015199.0010658.0092.00245260260249240255
  Retained Earnings113.8%14066.0014386.0024.001.00-58.91-125-342-433-474-547-583-609-603-569-544-529-531-529-501
  Additional Paid-In Capital-12.00-27.0013.00271262256407462501625646688668695814804789780769757
Shares Outstanding0.1%132132135135138138137142142138135137136137137146145145145144144
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations9.5%30627924024029228929926815211955.00-22.09-57.76-85.84-85.42-48.34-37.67-31.75-49.5093.00132
  Share Based Compensation14.4%32.0028.0024.0022.0021.0021.0021.0020.0019.0018.0017.0020.0024.0030.0035.0037.0037.0037.0036.0034.0033.00
Cashflow From Investing98.4%-7.92-497-487-784-800-410-406-48.38-61.52-5.0078.00-102-31.814.00-5.5512812267.002.00-157-162
Cashflow From Financing-185.3%-168197362200152-26078.00206223281-106132156126153-75.56-72.73-72.88-63.80-45.36-29.83
  Buy Backs0%35035020026786.00151-230224177150312254252200------

HALO Income Statement

2023-06-30
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues    
Total revenues$ 221,038$ 152,365$ 383,181$ 269,644
Operating expenses    
Cost of sales50,07033,94385,24049,865
Amortization of intangibles17,83511,40335,67011,403
Research and development19,72715,48337,70627,336
Selling, general and administrative38,94857,47676,30571,310
Total operating expenses126,580118,305234,921159,914
Operating income94,45834,060148,260109,730
Other income (expense)    
Investment and other income (expense), net3,192(945)6,171(447)
Interest expense(4,494)(3,104)(9,037)(4,863)
Net income before income taxes93,15630,011145,394104,420
Income tax expense18,4027,32631,02521,627
Net income$ 74,754$ 22,685$ 114,369$ 82,793
Earnings per share    
Basic (USD per share)$ 0.57$ 0.16$ 0.86$ 0.60
Diluted (USD per share)$ 0.56$ 0.16$ 0.84$ 0.58
Weighted average common shares outstanding    
Basic (shares)131,730137,937133,369137,798
Diluted (shares)133,543142,216135,758141,795
Royalties    
Revenues    
Total revenues$ 111,740$ 85,340$ 211,380$ 154,945
Product sales, net    
Revenues    
Total revenues73,88946,300134,68368,440
Revenues under collaborative agreements    
Revenues    
Total revenues$ 35,409$ 20,725$ 37,118$ 46,259

HALO Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 221,165,000$ 234,195,000
Marketable securities, available-for-sale127,110,000128,599,000
Accounts receivable, net and contract assets246,179,000231,072,000
Inventories, net132,406,000100,123,000
Prepaid expenses and other current assets38,885,00045,024,000
Total current assets765,745,000739,013,000
Property and equipment, net74,559,00075,570,000
Prepaid expenses and other assets18,409,00026,301,000
Goodwill416,821,000409,049,000
Intangible assets, net510,982,000546,652,000
Deferred tax assets, net23,924,00044,426,000
Restricted cash0500,000
Total assets1,810,440,0001,841,511,000
Current liabilities  
Accounts payable10,120,00017,693,000
Accrued expenses105,431,00096,516,000
Deferred revenue, current portion842,0003,246,000
Current portion of long-term debt, net013,334,000
Total current liabilities116,393,000130,789,000
Deferred revenue, net of current portion2,253,0002,253,000
Long-term debt, net1,495,998,0001,492,766,000
Other long-term liabilities30,875,00030,433,000
Contingent liability13,888,00015,472,000
Total liabilities1,659,407,0001,671,713,000
Commitments and contingencies (Note 12)
Stockholders’ equity  
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock - $0.001 par value; 300,000 shares authorized; 131,856 and 135,154 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively132,000135,000
Additional paid-in capital12,068,00027,368,000
Accumulated other comprehensive loss(1,615,000)(922,000)
Retained earnings140,448,000143,217,000
Total stockholders’ equity151,033,000169,798,000
Total liabilities and stockholders’ equity$ 1,810,440,000$ 1,841,511,000
Helen I. Torley
140
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.